Samsung Biologics Breaks Ground on Plant 4 in Songdo..."World's Largest Scale"

[Asia Economy Reporter Cho Hyun-ui] Samsung Biologics held a groundbreaking ceremony on the 18th at its global campus in Songdo, Incheon, announcing the start of construction for the world's largest Plant 4.

Scheduled to begin operations in 2023, Plant 4 will have a production capacity of 256,000 liters, surpassing the current world's largest single-plant facility, Plant 3, which has 180,000 liters. The total floor area will be approximately 238,000 square meters, nearly matching the combined floor area of Plants 1, 2, and 3, which is 240,000 square meters.

Plant 4 is a "super plant" capable of providing a one-stop service from cell line development to finished product manufacturing within a single facility. The company plans to accelerate the global supply of biopharmaceuticals and maximize customer satisfaction through this, securing a super-gap competitive edge.

Samsung Biologics will invest 1.74 trillion KRW solely in the construction of the plant. If additional land is secured for the second bio campus, which will house an open innovation R&D center and others, the total investment is estimated to exceed 2 trillion KRW.

With the construction of Plant 4, approximately 1,850 new employees will be hired, and an additional 6,400 construction workers will be employed separately. The production inducement effect is estimated at about 5.7 trillion KRW, and the employment creation effect is expected to reach approximately 27,000 jobs.

Samsung Biologics plans to support the government's policy to foster the materials, parts, and equipment industry by localizing key components used in Plant 4. On this day, the company signed a memorandum of understanding (MOU) with Jeonghyun Plant, a domestic bioreactor manufacturing specialist, agreeing to source all various types of bioreactors used in Plant 4 from Jeonghyun Plant.

Samsung Biologics stated, "Bioreactors are core equipment for large-scale proliferation of living cells, but localization has been difficult due to limitations in domestic technology. Together with Jeonghyun Plant, we will promote localization of technology and equipment to reduce costs and enhance production capacity." Samsung Biologics plans to continuously pursue localization projects to revitalize the national economy.

Kim Tae-han, CEO of Samsung Biologics, said, "We will continue to be a partner in continuous investment, biopharmaceutical development and technological innovation, market pioneering to enhance the global status of K-Bio, economic revitalization through export expansion, and youth job creation. We will take the lead in improving the health and quality of life of humanity."

This content was produced with the assistance of AI translation services.